Novo Nordisk Launches First‑Ever GLP‑1 Obesity Pill in the US

Danish pharmaceutical giant Novo Nordisk has officially launched the first oral GLP‑1 pill for obesity in the United States, marking a major milestone in weight‑management treatment options. The pill, branded as Wegovy®, contains semaglutide — the same active ingredient used in its widely known injectable formulations but now in a once‑daily tablet form designed to help adults with obesity or overweight shed excess body weight and keep it off long‑term. The U.S. Food and Drug Administration (FDA) cleared Wegovy® pill in December 2025, based on results from late‑stage clinical trials that showed people taking the pill experienced significant weight loss — averaging about 16.6% of body weight over 64 weeks compared with much smaller losses in placebo groups. Novo Nordisk has begun distribution nationwide in early January 2026, making the pill available across more than 70,000 pharmacies and through telehealth providers. Pricing starts around $149 per month for lower doses, with higher strengths available at elevated price points; insurance plans may reduce out‑of‑pocket costs. Company executives say the pill adds a more accessible, needle‑free option for people struggling with obesity — a condition affecting millions — and could expand treatment reach beyond those willing to use injections. Analysts also note this launch intensifies competition in the rapidly growing obesity drug market, particularly with rival Eli Lilly’s oral GLP‑1 drug still under review. #WegovyPill #NovoNordisk #ObesityTreatment #GLP1 #SlimScan #GrowthStocks #CANSLIM